Predictors of outcome in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 21, Issue 9, 2015, Pages 2097-2105

  Waterman, Matti ^a,b   Knight, Jo ^c,d   Dinani, Amreen ^a   Xu, Wei ^d   Stempak, Joanne M ^a   Croitoru, Kenneth ^a,d   Nguyen, Geoffrey C ^a,d   Cohen, Zane ^a   McLeod, Robin S ^a,d   Greenberg, Gordon R ^a,d   Steinhart, A Hillary ^a,d   Silverberg, Mark S ^a,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b RAMBAM MEDICAL CENTER   (Israel)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Genetic markers; Immunochip; Prognosis; Proximal disease; Serum markers; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; DNA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLIXIMAB; MERCAPTOPURINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; CBIR1 FLAGELLIN; FLAGELLIN; FUNGUS ANTIBODY; OUTER MEMBRANE PROTEIN C; PORIN;

ADOLESCENT; ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL FEATURE; COLON RESECTION; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC MARKER; GENOTYPE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE; ULCERATIVE COLITIS; AGE; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CHILD; COLITIS, ULCERATIVE; DISEASE COURSE; GENETICS; IMMUNOLOGY; MIDDLE AGED; ODDS RATIO; ONSET AGE; PREDICTIVE VALUE; PRESCHOOL CHILD; SACCHAROMYCES CEREVISIAE; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, FUNGAL; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COLECTOMY; COLITIS, ULCERATIVE; DISEASE PROGRESSION; FEMALE; FLAGELLIN; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PORINS; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SACCHAROMYCES CEREVISIAE; YOUNG ADULT;

EID: 84940947476     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000466     Document Type: Article

References (33)

1. Meucci G, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie In-testinali (GSMII). Am J Gastroenterol. 2000;95:469-473.
2. Robert JH, et al. Management of severe hemorrhage in ulcerative colitis. Am J Surg. 1990;159:550-555.
3. Langholz E, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3-11.
4. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126:1504-1517.
5. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut. 1990;31:329-333.
6. Langholz E, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992;103:1444-1451.
7. Louis E, Belaiche J, Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol. 2010;16: 2600-2603.
8. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041-1048.
9. Silverberg MS, et al. Toward an integrated clinical, molecular and sero-logical classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
10. Satsangi J, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
11. Solberg IC, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-440.
12. Chow DK, et al. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study. Aliment Pharmacol Ther. 2009;29:843-854.
13. Haritunians T, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:1830-1840.
14. Zholudev A, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastro-enterol. 2004;99:2235-2241.
15. Preda CM, et al. Prevalence and significance of perinuclear anti-neutrophil antibodies (pANCA) in Romanian patients with Crohn's disease and ulcerative colitis. Rom J Gastroenterol. 2005;14:357-360.
16. Solberg IC, et al. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:406-414.
17. de la Concha EG, et al. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenter-ology. 2000;119:1491-1495.
18. Heresbach D, et al. Are HLA-DR or TAP genes genetic markers of severity in ulcerative colitis? J Autoimmun. 1996;9:777-784.
19. Bouma G, et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol. 1999;115:294-300.
20. Nemetz A, et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics. 1999;49:527-531.
21. Potocnik U, et al. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 2004;5:530-539.
22. Nam SY, et al. Heat shock protein gene 70-2 polymorphism is differentially associated with the clinical phenotypes of ulcerative colitis and Crohn's disease. J Gastroenterol Hepatol. 2007;22:1032-1038.
23. Jurgens M, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811-1819.
24. Fowler EV, et al. ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity. Am J Gastroenterol. 2008;103:2519-2526.
25. Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491: 119-124.
26. Landers CJ, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto and microbial antigens. Gastroen-terology. 2002;123:689-699.
27. Cortes A, Brown MA. Promise and pitfalls of the immunochip. Arthritis Res Ther. 2011;13:101.
28. Romberg-Camps MJ, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104:371-383.
29. Boyko EJ, et al. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol. 1988;23:1147-1152.
30. Szamosi T, et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reopera-tion in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010;22:872-879.
31. Falcone RA Jr, Lewis LG, Warner BW. Predicting the need for colectomy in pediatric patients with ulcerative colitis. J Gastrointest Surg. 2000;4:201-206.
32. Festen EA, et al. Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk. Am J Gastroenterol. 2010;105:395-402.
33. Guo C, et al. Association of caspase-9 and RUNX3 with inflammatory bowel disease. Tissue Antigens. 2011;77:23-29.